We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
+10.92%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$43.9B
AUM Growth
+$2.87B
(+7%)
Cap. Flow
-$890M
Cap. Flow
% of AUM
-2.03%
Top 10 Holdings %
Top 10 Hldgs %
13.25%
Holding
2,343
New
170
Increased
997
Reduced
1,015
Closed
150
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$111M |
| 2 |
Verizon
VZ
|
+$103M |
| 3 |
AT&T
T
|
+$103M |
| 4 |
Kroger
KR
|
+$97.1M |
| 5 |
3M
MMM
|
+$92.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$138M |
| 2 |
Tesla
TSLA
|
+$110M |
| 3 |
JPMorgan Chase
JPM
|
+$103M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$89.4M |
| 5 |
Apple
AAPL
|
+$85.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.57% |
| 2 | Healthcare | 16.25% |
| 3 | Financials | 11.85% |
| 4 | Industrials | 11.44% |
| 5 | Consumer Discretionary | 10.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2001
Bioventus
BVS
$1.17B
| $273K | ﹤0.01% |
+104,471
| New | +$456K |
|
2002
BRC Group Holdings
RILY
$298M
| $272K | ﹤0.01% |
7,961
-459
| -5% | -$19.2K |
|
2003
Cogent Biosciences
COGT
$6.74B
| $272K | ﹤0.01% |
+23,549
| New | +$292K |
|
2004
Costamare
CMRE
$1.71B
| $271K | ﹤0.01% |
29,221
+18,201
| +165% | +$171K |
|
2005
Shutterstock
SSTK
$211M
| $271K | ﹤0.01% |
5,140
-10,224
| -67% | -$521K |
|
2006
Zillow
Z
$7.58B
| $269K | ﹤0.01% |
8,501
-4,756
| -36% | -$158K |
|
|
BLUE
2007
DELISTED
bluebird bio
BLUE
| $266K | ﹤0.01% |
1,965
-837
| -30% | -$118K |
|
|
RPTX
2008
DELISTED
Repare Therapeutics
RPTX
| $262K | ﹤0.01% |
+17,807
| New | +$266K |
|
2009
Arvinas
ARVN
$581M
| $261K | ﹤0.01% |
7,623
-8,425
| -52% | -$354K |
|
|
SPR
2010
DELISTED
Spirit AeroSystems
SPR
| $261K | ﹤0.01% |
9,118
-60,088
| -87% | -$1.56M |
|
2011
Pathward Financial
CASH
$1.82B
| $260K | ﹤0.01% |
6,033
-4,774
| -44% | -$196K |
|
2012
Amplify Energy
AMPY
$182M
| $259K | ﹤0.01% |
29,475
| – | – |
|
2013
Tennant Co
TNC
$1.17B
| $258K | ﹤0.01% |
+4,188
| New | +$256K |
|
2014
CryoPort
CYRX
$762M
| $257K | ﹤0.01% |
+14,806
| New | +$312K |
|
|
HLGN
2015
DELISTED
Heliogen, Inc.
HLGN
| $257K | ﹤0.01% |
10,505
+10,136
| +2,747% | +$457K |
|
2016
Northwest Bancshares
NWBI
$2.28B
| $256K | ﹤0.01% |
+18,295
| New | +$264K |
|
2017
Brinker International
EAT
$9.72B
| $256K | ﹤0.01% |
8,013
-31,320
| -80% | -$985K |
|
2018
Helix Energy Solutions
HLX
$1.51B
| $255K | ﹤0.01% |
34,620
-80,757
| -70% | -$485K |
|
|
MAGN
2019
Magnera Corp
MAGN
$462M
| $255K | ﹤0.01% |
7,068
-1,830
| -21% | -$74.7K |
|
2020
Foghorn Therapeutics
FHTX
$384M
| $254K | ﹤0.01% |
39,817
-30,770
| -44% | -$232K |
|
|
HIBB
2021
DELISTED
Hibbett, Inc. Common Stock
HIBB
| $254K | ﹤0.01% |
3,721
-2,989
| -45% | -$186K |
|
|
TWOU
2022
DELISTED
2U Inc
TWOU
| $253K | ﹤0.01% |
1,383
-2,616
| -65% | -$519K |
|
2023
Triumph Financial Inc
TFIN
$1.81B
| $253K | ﹤0.01% |
5,175
+188
| +4% | +$10.2K |
|
2024
Alphatec Holdings
ATEC
$1.46B
| $251K | ﹤0.01% |
20,332
+82
| +0.4% | +$826 |
|
2025
Gorman-Rupp
GRC
$2.19B
| $251K | ﹤0.01% |
9,783
-21,529
| -69% | -$569K |
|
Similar funds
VGA
AQR Capital Management's Q4 2022 Portfolio in Review
As of Q4 2022, AQR Capital Management held 2,343 positions worth $43.9B, up 7% from $41B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
AQR Capital Management's Q4 2022 filing shows 170 new, 997 increased, 1,015 reduced and 150 closed positions. Its largest new stake was Generac Holdings: 310,080 shares worth $30.5M. The largest sale was Gilead Sciences, an estimated $138M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q4 2022 buy was Generac Holdings: 310,080 shares worth $30.5M.
- AQR Capital Management added most to Humana in Q4 2022, an estimated $111M increase.
- AQR Capital Management's biggest Q4 2022 reduction was Gilead Sciences, cutting an estimated $138M.
- AQR Capital Management fully exited Abiomed Inc in Q4 2022, selling an estimated $22.4M.
- AQR Capital Management's ten largest holdings make up 13% of its $43.9B portfolio in Q4 2022.
- AQR Capital Management opened 170 new positions and closed 150 in Q4 2022.
- AQR Capital Management's portfolio value rose 7% quarter-over-quarter to $43.9B.
Based on AQR Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.